The table below shows Intellia Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$117.35M
-$148.93M
-$120.66M
-$109.33M
-$79.80M
-$52.38M
Capital expenditure
$79.00K
$735.00K
$2.51M
$3.83M
$1.43M
$2.41M
Investing cash flow
$66.31M
$94.33M
$5.90M
-$122.25M
$47.47M
-$25.54M
Dividends paid
-
-
-
-
NTLA operating cash flow (10-K history)
Intellia Therapeutics, Inc. reported operating cash flow of -$394.74M for fiscal year 2025. That is down 13.1% from -$348.88M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $36.11M (FY 2016) to -$394.74M. Figures come from the company's audited annual reports as filed with the SEC.
